Compared to conventional techniques using ES cells, the production period can be shortened by 4 to 6 months.
Introducing the "TurboKnockout Gene Targeting Mouse." Genetically modified mice and rats are widely used in biological and medical research, but the design and production of these models are complex and require significant time and cost. Our service can produce conditional knockout and knock-in mouse models in as little as 6 months, reducing the time by 4 to 6 months compared to traditional methods. This utilizes gene targeting technology with ES cells. 【Features】 ■ Can be produced in a short period ■ Reduces breeding by 2 generations *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Types of Targeting Mice】 ■ Conventional Knockout ■ Conditional Knockout ■ Knock-in ■ Humanized Mouse ■ KO-First *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
In 2005, we were established as a contract research organization for pharmaceutical development and a manufacturer of cell-related products. Currently, we have 400 employees worldwide. Our headquarters is located in Silicon Valley, California, USA, with manufacturing bases in Suzhou and Guangzhou, China. In 2016, we opened a branch in Tokyo, Japan. As a leading company in the production of genetically modified animal models, we provide high-quality reagents and tools at reasonable prices. 1. Production of genetically modified animal models: As a leading company in the contract production of rodent animal models, we offer a one-stop service that is optimal for research. Our services cover a wide range, including vector construction, ES cell manipulation, and microinjection production, allowing us to accept contracts for animal model production at any stage of the process. We are also engaged in contract services for animal models using the CRISPR-Cas9 system and artificial nuclease technology. The artificial nuclease technology can save time and costs compared to traditional gene targeting techniques.